Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Akebia Therapeutics Inc | AKBA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.37 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.37 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.5895 - 2.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.37 | USD |
Akebia Therapeutics (AKBA) Options Flow Summary
Akebia Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 286.84M | 209.37M | - | 194.62M | -51.93M | -0.25 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Akebia Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AKBA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.52 | 1.54 | 1.32 | 1.41 | 3,520,511 | -0.15 | -9.87% |
| 1 Month | 2.07 | 2.48 | 1.32 | 1.76 | 9,013,369 | -0.70 | -33.82% |
| 3 Months | 1.48 | 2.48 | 1.32 | 1.71 | 5,027,940 | -0.11 | -7.43% |
| 6 Months | 0.8677 | 2.48 | 0.7801 | 1.58 | 3,163,928 | 0.5023 | 57.89% |
| 1 Year | 0.6617 | 2.48 | 0.5895 | 1.44 | 2,474,668 | 0.7083 | 107.04% |
| 3 Years | 2.93 | 4.33 | 0.241 | 1.33 | 3,779,926 | -1.56 | -53.24% |
| 5 Years | 6.77 | 13.78 | 0.241 | 2.43 | 3,484,936 | -5.40 | -79.76% |
Akebia Therapeutics Description
| Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. |
